 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
|
|
|
|
Phase III, Phase II
|
|
|
|
RPCI-RP-9815
NCI-V99-1527, NCT00003816, RP 98-15
|
|
| |
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
|
|
|
|
Phase III, Phase II
|
|
|
|
GC P#02.01.001
NCT00469729
|
|
| |
In-Vivo Activated T-Cell Depletion to Prevent GVHD
|
|
|
|
Phase III, Phase II
|
|
|
|
0705-20 IUCRO-0196
NCT00594308
|
|
| |
Chemotherapy With or Without Total-Body Irradiation in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Myelodysplastic Syndromes or Acute Myeloid Leukemia
|
|
|
|
Phase III
|
|
|
|
FHCRC-1992.00
6170, NCT00322101, NHLBI-K23-HL084054-01A1
|
|
| |
Comparing Peripheral Blood Stem Cell Transplantation Versus Bone Marrow Transplantation in Individuals With Hematologic Cancers
|
|
|
|
Phase III
|
|
|
|
418
BMTCTN-0201, NCT00075816
|
|
| |
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
|
|
|
|
Phase III
|
|
|
|
SCT 0307
NCT00619879
|
|
| |
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD)
|
|
|
|
Phase III
|
|
|
|
385
BMT CTN 0402, U01 HL069294-05, NCT00406393
|
|
| |
Chemotherapy Followed by Allogeneic Stem Cell Transplantation in Treating Children With Hematologic Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
NCI-01-C-0125F
NCT00020592
|
|
| |
Donor Peripheral Stem Cell Transplant in Treating Patients With
Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative
Disorder
|
|
|
|
Phase II, Phase I
|
|
|
|
FHCRC-1628.00
NCI-H02-0099, NCT00049634
|
|
| |
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Allogeneic Transplantation
|
|
|
|
Phase II, Phase I
|
|
|
|
FHCRC-1803.00
5606, NCT00068718
|
|
